| __timestamp | CymaBay Therapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 90480000 |
| Thursday, January 1, 2015 | 8871000 | 133384000 |
| Friday, January 1, 2016 | 9645000 | 179997000 |
| Sunday, January 1, 2017 | 12387000 | 220119000 |
| Monday, January 1, 2018 | 14381000 | 258528000 |
| Tuesday, January 1, 2019 | 19238000 | 198205000 |
| Wednesday, January 1, 2020 | 17425000 | 181022000 |
| Friday, January 1, 2021 | 23040000 | 198359000 |
| Saturday, January 1, 2022 | 25116000 | 208789000 |
| Sunday, January 1, 2023 | 51953000 | 211124000 |
Unleashing insights
In the competitive landscape of biotechnology and medical devices, understanding financial health is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group consistently outspent CymaBay, with its SG&A expenses peaking at approximately $211 million in 2023, a 133% increase from 2014. In contrast, CymaBay's expenses surged by over 500%, reaching around $52 million in 2023. This stark difference highlights MiMedx's larger operational scale and market presence. However, CymaBay's rapid growth in expenses could indicate aggressive expansion strategies. Investors and stakeholders should consider these trends when evaluating the companies' strategic directions and financial sustainability.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
argenx SE vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: United Therapeutics Corporation vs MiMedx Group, Inc.
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
CymaBay Therapeutics, Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: PTC Therapeutics, Inc. vs MiMedx Group, Inc.